{"prompt": "['2016N277425_01', 'CONFIDENTIAL', '2018N377698_0', '201749', 'Blinded Treatment', 'Pre-', 'Screen/', 'Rando-', 'Telephone Follow up', 'screen\u00b9', 'Run-in', 'mization', 'EW', 'contact', 'Visit', '0', '1', '2', '3', '4', '5', 'Visit 2', '6', 'Week', '-6 to -4', '-4', '0', '4', '12', '24', '42 +2', '28  2', '1=2 -7/+2', '28 +2 -7/+2', '84 2', '168 2 -7/+2', '7+ 23 days after V5', '-7/+2', '-7/+2 days', 'days', 'days', 'days', 'days', 'or EW Visit', 'days', 'prior Visit', 'prior', '2', 'Day', 'Visit 1', 'Efficacy/HRQoL assessments', 'Spirometry, including pre-dose FEV1, trough FEV1 and', 'X', 'X', 'X', 'X', 'inspiratory capacity', 'SAC BDI questionnaire 4', 'X', 'SAC TDI questionnaire 4', 'X', 'X', 'X', 'SGRQ-C questionnaire 4', 'X', 'X', 'X', 'X', 'CAT questionnaire 4', 'X', 'X', 'X', 'X', 'EXACT/ER-S: COPD 5', 'Patient Global Rating of COPD severity', 'X', 'X', 'X', 'X', 'Patient Global Rating of Change in COPD', 'X', 'X', 'X', 'Safety assessments', 'Adverse events/Serious adverse events 6', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'COPD exacerbation assessment', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '12-Lead ECG', 'Urine pregnancy test 7', 'X', 'X', 'Pharmacogenetic sample8', 'X', 'Medication/Supplies', 'Dispense rescue albuterol/slabutamol. Dispense MDI9', 'X', 'X', 'Assess COPD medication compliance10 during run-in', 'X', 'Dispense eDiary', 'X', 'Assess compliance with eDiary during run-in', 'X', 'Collect rescue albuterol/slabutamol.', 'X', 'X', 'X', 'Collect eDiary', 'X', 'X', 'Dispense study treatment11', 'X', '93']['2016N277425_01', 'CONFIDENTIAL', '2018N377698_0', '201749', 'Blinded Treatment', 'Pre-', 'Screen/', 'Rando-', 'Telephone Follow up', 'screen\u00b9', 'Run-in', 'mization', 'EW', 'contact', 'Visit', '0', '1', '2', '3', '4', '5', 'Visit 2', '6', 'Week', '-6 to -4', '-4', '0', '4', '12', '24', '42 +2', '28  2', '1=2-7/+2', '28 +2 -7/+2', '84 2', '168 2 -7/+2', '7+ 23 days after V5', '-7/+2', '-7/+2 days', 'days', 'days', 'days', 'days', 'or EW Visit', 'days', 'prior Visit', 'prior', '2', 'Day', 'Visit 1', 'Collect study treatment', 'X', 'X', 'X', 'Assess study treatment compliance during treatment10', 'X', 'X', 'Study sub-set', 'Physical activity monitor12', 'X', 'X', 'X', 'Collect Physical activity monitor', 'X', '1.', 'Pre-screen Visit 0 must be completed prior to Screening Visit1. It can be completed 2 weeks prior or on the same day of V1, if no wash out of exclusionary medications is', 'required.', '2. Early Withdrawal Visit: Subjects that withdraw should return to the clinic as soon as possible to complete the Early Withdrawal Visit procedures.', '3.', 'Spirometry at screening should be performed as described in (Section 7.2.2.1).', '4. SAC BDI, SAC TDI, SGRQ-C, CAT questionnaires will be completed at clinic visits and in the eDiary', '5.', 'EXACT/ER-S: COPD is completed daily in the eDiary approximately 2 hours before bed-time, starting on Day 1 of the run-in period.', '6.', 'For the start date of collecting AEs and SAEs see (Appendix 4)', '7.', 'Pregnancy test: for females for child bearing potential only.', '8.', 'Pharmacogenetic sample may be drawn at visit 2 or any visit after.', '9. Rescue medication use to be recorded in the eDiary daily and in some sites in the eDiary and the eMDI', '10. Sites are requested to call subjects every 2 weeks to remind them to take study treatment regularly and to record the time of the morning and evening dose in the eDiary.', '11. In order to ensure subjects have sufficient doses of study treatment, they must return to clinic within 30 days from V2 and within 60 and 90 days from V3 and V4 respectively.', '12.', 'The Actigraph GT9X should be worn for 7 days from Visit 1, for 7 days from Visit 2, for 7 days from Visit 3 and for 7 days prior to Visit 5.', '94']\n\n###\n\n", "completion": "END"}